Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Cytotoxic Action of Brazilian Propolis In Vitro on Canine Osteosarcoma Cells

Texto completo
Autor(es):
Cinegaglia, N. C. [1] ; Bersano, P. R. O. [2] ; Bufalo, M. C. [1] ; Sforcin, J. M. [1]
Número total de Autores: 4
Afiliação do(s) autor(es):
[1] Univ Estadual Paulista, Biosci Inst, Dept Microbiol & Immunol, BR-18618970 Sao Paulo - Brazil
[2] Sao Paulo State Univ UNESP, Coll Vet Med & Anim Husb, Invest & Comparat Pathol Lab, BR-18618970 Sao Paulo - Brazil
Número total de Afiliações: 2
Tipo de documento: Artigo Científico
Fonte: Phytotherapy Research; v. 27, n. 9, p. 1277-1281, SEP 2013.
Citações Web of Science: 11
Resumo

Osteosarcoma (OSA) is a primary bone neoplasm frequently diagnosed in dogs. The biology of OSA in pet dogs is identical to that of pediatric patients, and it has been considered an excellent model in vivo to study human OSA. Since the individual response to chemotherapy is unpredictable and considering that propolis is a natural product with several biological properties, this work evaluated the cytotoxic action of propolis on canine OSA cells. The primary cell culture of canine OSA was obtained from the tumor of a dog with OSA. Cell viability was assessed after incubation with propolis, 70% ethanol (propolis solvent), and carboplatin after 6, 24, 48, and 72h. Cell viability was analyzed by the crystal violet method. Data showed that canine OSA cells were sensitive to propolis in a dose- and time-dependent manner and had a distinct morphology compared to control. Its solvent (70% ethanol) had no effect on cell viability, suggesting that the cytotoxic action was exclusively due to propolis. Our propolis sample exerted a cytotoxic effect on canine OSA cells, and its introduction as a possible therapeutic agent in vivo could be investigated, providing a new contribution to OSA treatment. Copyright (c) 2012 John Wiley \& Sons, Ltd. (AU)

Processo FAPESP: 09/53493-9 - Expressão in vitro da cicloxigenase-2 (COX2) no osteossarcoma exposto a inibidor seletivo da COX2
Beneficiário:Noeme Sousa Rocha
Modalidade de apoio: Auxílio à Pesquisa - Regular